If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Nidogen-1 (NID-1), formerly known as entactin, is a protein that in humans is encoded by the NID1 gene. Both nidogen-1 and nidogen-2 are essential components of the basement membrane alongside other components such as type IV collagen, proteoglycans (heparan sulfate and glycosaminoglycans), laminin and fibronectin.
===== Chitosan ===== Chitosan hemostats are topical agents composed of chitosan and its salts. Chitosan bonds with platelets and red blood cells to form a gel-like clot which seals a bleeding vessel. Unlike other hemostatic agents like kaolin, its action does not require the normal hemostatic pathway and therefore continues to function even when anticoagulants like heparin are present in the patient's body, or when the patient's hemostatic ability is impaired due to the patient being hypothermic or hypovolemic. Chitosan is used in some emergency hemostats which are designed to stop traumatic life-threatening bleeding. Their use is well established in many military and trauma units.
== External links == Indium Archived 2023-03-13 at the Wayback Machine at The Periodic Table of Videos (University of Nottingham) Reducing Agents > Indium low valent Archived 2023-07-09 at the Wayback Machine NIOSH Pocket Guide to Chemical Hazards Archived 2015-12-08 at the Wayback Machine (Centers for Disease Control and Prevention) usgs.gov (Mineral Commodity Summaries 2025): Indium
Chia seeds ( CHEE-ə) are the edible seeds of Salvia hispanica, a flowering plant in the mint family (Lamiaceae) native to central and southern Mexico, or of the related Salvia columbariae, Salvia polystachia, or Salvia tiliifolia. Chia seeds are oval and gray with black and white spots, and have a diameter of around 1–2 millimetres (0.04–0.08 in). The seeds are hygroscopic, absorbing up to 12 times their weight in liquid when soaked and developing a mucilaginous coating that gives chia-based foods and beverages a distinctive gel texture. There is evidence that the crop was widely cultivated by the Aztecs in pre-Columbian times and was a staple food for Mesoamerican cultures. Chia seeds are cultivated on a small scale in their ancestral homeland of central Mexico and Guatemala and commercially throughout Central and South America.
As JD Vance and Marco Rubio met the Danish and Greenlandic foreign ministers Lars Løkke Rasmussen and Vivian Motzfeldt, the White House posted a meme on Twitter with the question: "Which way, Greenland man?" with imagery implying a choice between the United States and an ominous-looking China and Russia. Heidi Beirich of the Global Project Against Hate and Extremism described the meme as reflecting a key concept in neo-Nazi and white supremacist subculture, explaining that "Western man is code for white man, and one of the most popular racist books in these subcultures is Which Way Western Man, which has been featured in a Department of Homeland Security post celebrating manifest destiny." Trump has engaged in online trolling, posting an altered image that features the US flag covering Canada, Greenland, and Venezuela and an AI image of himself planting a US flag in Greenland, marked as "US territory" and "EST. 2026." Paul Buvarp, a researcher on disinformation and propaganda at the Norwegian Defence Research Establishment, described Trump's claims about imminent Chinese and Russian threats to Greenland as detached from observable reality and emblematic of information manipulation rather than genuine security analysis. Buvarp argued that the rhetoric functions as propaganda by deliberately creating uncertainty, anxiety, and confusion. On 29 January 2026, German broadcaster Norddeutscher Rundfunk was fined by Greenlandic police after comic artist Maxi Schafroth attempted to raise the US flag near a cultural centre in Nuuk as part of a stunt.
Sources: en.wikipedia.org
== Pharmacokinetics == Citicoline is water-soluble, with more than 90% oral bioavailability. Plasma levels of citicholine peak one hour after oral ingestion, and a majority of the citicoline is excreted as CO2 in respiration with the remaining citicoline being excreted through urine. The pharmacokinetic profile of citicholine cannot be described by a single smooth exponential decrease over time. However, the elimination half-life for citicholine has been reported as approximately 50 hours for citicholine removed via respiration and approximately 70 hours for citicholine removed via urine. Plasma levels of choline peak about four hours after ingestion.
Cycloheximide chase assays are an experimental technique used in molecular and cellular biology to measure steady state protein stability. Cycloheximide is a drug that inhibits the elongation step in eukaryotic protein translation, thereby preventing protein synthesis. The addition of cycloheximide to cultured cells followed by proteolysis at multiple timepoints is conducted to observe protein degradation over time and can be used to determine a protein's half-life. These assays are often followed by western blotting to assess protein abundance and can be analyzed using quantitative tools such as ImageJ. Implementation Cycloheximide chase assays have been conducted using a variety of eukaryotic cells such as yeast and mammalian cell lines. Depending on the cell system used for analysis, the assay may vary in application and time course. For example, yeast cells expressing a protein substrate of interest typically require cycloheximide chases lasting up to 90 minutes to allow protein turnover to occur. In contrast, proteins that are expressed in mammalian cell lines tend to me more stable at steady state and may require a chase lasting 3 to 8 hours. Depending on the complexity of the protein and whether it is overexpressed or endogenous to the model system, the required length of the chase may vary. To ensure that protein synthesis is inhibited during the entire chase, cycloheximide is often spiked into the sample every few hours. In yeast, deletion strains are frequently used to assess protein stability over time with cycloheximide chases.
However, the biological effects of radiation due to radioactive substances were less easy to gauge. This gave the opportunity for many physicians and corporations to market radioactive substances as patent medicines. Examples were radium enema treatments, and radium-containing waters to be drunk as tonics. Marie Curie protested against this sort of treatment, warning that "radium is dangerous in untrained hands". Curie later died from aplastic anaemia, likely caused by exposure to ionizing radiation. By the 1930s, after a number of cases of bone necrosis and death of radium treatment enthusiasts, radium-containing medicinal products had been largely removed from the market (radioactive quackery).
(CH2CH2)O + HCN → HOCH2CH2CN →−H2O CH2=CH−CN Addition of hydrocyanic acid to ethylene oxide is carried out in the presence of a catalyst (sodium hydroxide and diethylamine), and dehydration of cyanohydrin occurs in the gas phase upon the catalytic action of aluminium oxide.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.